Mga Batayang Estadistika
| LEI | 549300UB28QGWJMFFA11 |
| CIK | 1035354 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Eloxx Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-31326 CUSIP Number: 29014R103 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2025 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Trans |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-31326 CUSIP Number: 29014R103 (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2025 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Tran |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-31326 CUSIP Number: 29014R103 (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2024 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ T |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-31326 CUSIP Number: 29014R103 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2024 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ |
|
| October 17, 2024 |
ELOXX PHARMACEUTICALS, INC. AMENDMENT TO STOCK OPTION AGREEMENT Exhibit 10.1 ELOXX PHARMACEUTICALS, INC. AMENDMENT TO STOCK OPTION AGREEMENT This Amendment to Stock Option Agreement (the “Amendment”) is made as of October 16, 2024 between the undersigned Participant (“Participant”) and Eloxx Pharmaceuticals, Inc. (the “Company”). WHEREAS, as evidenced by the option grant notice(s) (each, a “Grant Notice”) and Stock Option Agreement(s) (each, an “Agreement”), t |
|
| October 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commi |
|
| August 20, 2024 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D/A EX-1 2 exhibit1.htm EXHIBIT 1 Exhibit I AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D/A Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13D/A to which this Agreement is attached as an Exhibit, and any amendments thereto, will be filed with the Se |
|
| August 20, 2024 |
ELOX / Eloxx Pharmaceuticals, Inc. / Advent Life Sciences LLP - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Eloxx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 29014R103 (CUSIP Number) Kaasim Mahmood Advent Life Sciences LLP 27 Fitzroy Square London W1T 6ES United Kingdom +44 (0) 207 932 2100 (N |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-31326 CUSIP Number: 29014R103 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2024 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Trans |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-31326 CUSIP Number: 29014R103 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2024 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Tran |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-31326 CUSIP Number: 29014R103 (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Tr |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| March 14, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| January 25, 2024 |
COMMON STOCK PURCHASE WARRANT ELOXX PHARMACEUTICALS, INC. Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 25, 2024 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is made as of January 98, 2024 (the “Effective Date”) by and between Eloxx Pharmaceuticals, Inc, a Delaware corporation (the “Company”), and SD MF 4 LLC, a Delaware limited liability company (the “Purchaser”). 1. Issuance of Securities. Subject to the terms and conditions |
|
| January 25, 2024 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT Eloxx Pharmaceuticals, Inc. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 25, 2024 |
Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) ELOXX PHARMACEUTICALS, INC. |
|
| January 25, 2024 |
As filed with the Securities and Exchange Commission on January 24, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 24, 2024 File No. |
|
| January 24, 2024 |
As filed with the Securities and Exchange Commission on January 24, 2024 As filed with the Securities and Exchange Commission on January 24, 2024 Registration No. |
|
| January 24, 2024 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLES FORM S-8 (Form Type) Eloxx Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commis |
|
| December 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Comm |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Comm |
|
| November 13, 2023 |
Eloxx Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice (2018 Equity Incentive Plan) Exhibit 10.2 Eloxx Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice (2018 Equity Incentive Plan) Eloxx Pharmaceuticals, Inc. (the “Company”), pursuant to its 2018 Equity Incentive Plan (as amended, the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award |
|
| November 13, 2023 |
ELOXX PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2018 EQUITY INCENTIVE PLAN) Exhibit 10.3 ELOXX PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2018 EQUITY INCENTIVE PLAN) Eloxx Pharmaceuticals, Inc. (the “Company”), pursuant to its 2018 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Sto |
|
| November 13, 2023 |
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.4 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of May 19, 2023 (the “Amendment Signing Date”), is entered into by and among ELOXX PHARMACEUTICALS, INC., a Delaware corporation (“Eloxx”), ZIKANI THERAPEUTICS, INC., a Delaware corporation (“Zikani” and, together with Eloxx, individually or collectively, a |
|
| November 13, 2023 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT Eloxx Pharmaceuticals, Inc. Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Eloxx Pharmaceuticals, Inc. Warrant Shares: 75,000 Issue Date: September 20, 2023 Initial Exercise Date: September 20, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations o |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUT |
|
| November 13, 2023 |
COMMON STOCK PURCHASE WARRANT Eloxx Pharmaceuticals, Inc. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| November 13, 2023 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome ELX-02 improved podocyte foot process effacement in all three treated patients |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Comm |
|
| November 13, 2023 |
THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.5 Execution Version THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of November 10, 2023, is entered into by and among ELOXX PHARMACEUTICALS, INC., a Delaware corporation (“Eloxx”), ZIKANI THERAPEUTICS, INC., a Delaware corporation (“Zikani” and, together with Eloxx, individually or collectively, as the cont |
|
| November 13, 2023 |
Exhibit 4.3 SCHEDULE OF WARRANT HOLDERS In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the omitted executed warrants differ from the form of warrant that follows: Holder Warrant Shares Michael Vasinkevich 14,643 Noam Rubinstein 7,193 Craig Schwabe 771 Charles Worthman 228 Total 22,835 ||| Exhibit 4.3 NEITHER THIS SECURITY NOR THE |
|
| November 13, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 18, 2023, between Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co |
|
| October 16, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commi |
|
| September 20, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-258994 PROSPECTUS SUPPLEMENT (To Prospectus dated August 30, 2021) 305,590 Shares of Common Stock Pre-Funded Warrants to Purchase up to 75,000 Shares of Common Stock Up to 75,000 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering pursuant to this prospectus supplement and accompanying prospectus to an |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Com |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Com |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Com |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Comm |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commis |
|
| August 21, 2023 |
Exhibit 99.1 RARE Thinking for RARE Solutions Small Molecule Gene Therapy August 2023 / 2 Forward-looking statements This presentation contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar express |
|
| August 21, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commis |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commis |
|
| August 14, 2023 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy, demonstrating the disease-modifying effect of ELX-02 Announced achievement |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUTICALS |
|
| August 11, 2023 |
ELOXX PHARMACEUTICALS, INC. Up to $4,200,000 of Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-258994 PROSPECTUS SUPPLEMENT (To Prospectus dated August 30, 2021 and Prospectus Supplement dated May 24, 2023) ELOXX PHARMACEUTICALS, INC. Up to $4,200,000 of Common Stock This Prospectus Supplement supplements the prospectus and the prospectus supplement, dated August 30, 2021 and May 24, 2023, respectively (together, the “ATM Prospectus”) |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| July 13, 2023 |
Exhibit 99.1 / 1 Baseline characteristics of patients that have completed therapy Patient Age Sex COl4 Gene Affected Nonsense Mutation RAAS Block dose Cr (mg/dL) Proteinuria (mg/g) 4401 - 01 13 Male COL4A4 c.2906C>G*; p.Ser969X Enalapril 2.5 mg QD 0.7 1299 4401 - 02 13 Male COL4A4 c.2906C>G*; p.Ser969X Enalapril 32.5 mg QD 0.5 1646 4402 - 01 19 Female COL4A4 c.2906C>G*; p.Ser969X Enalapril 5 mg QD |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissio |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissio |
|
| May 24, 2023 |
Exhibit 1.1 ELOXX PHARMACEUTICALS, INC. Shares of Common Stock ($0.01 par value per share) SALES AGREEMENT May 24, 2023 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Eloxx Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc. (the “Agent”), as follows: 1. Issuance and Sale of Shares. The Compa |
|
| May 24, 2023 |
ELOXX PHARMACEUTICALS, INC. Up to $6,500,000 Common Stock TABLE OF CONTENTS As Filed Pursuant to Rule 424(b)(5) Registration No. 333-258994 PROSPECTUS SUPPLEMENT (To Prospectus dated August 30, 2021) ELOXX PHARMACEUTICALS, INC. Up to $6,500,000 Common Stock We have entered into a Sales Agreement (the “Sales Agreement”), with Oppenheimer & Co. Inc. (“Oppenheimer”), dated May 24, 2023, relating to the sale of shares of our common stock, $0.01 par value p |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissio |
|
| May 16, 2023 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for the potential treatment of Alport syndrome expected in first half of 2023; meaningful protein reduction has been observed in one patient to date Received U.S. Food and Drug Administr |
|
| May 12, 2023 |
Exhibit 10.1 EXECUTION VERSION FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of March 7, 2023 (the “Amendment Signing Date”), is entered into by and among ELOXX PHARMACEUTICALS, INC., a Delaware corporation (“Eloxx”), ZIKANI THERAPEUTICS, INC., a Delaware corporation (“Zikani” and, together with Eloxx, individually o |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUTICAL |
|
| April 28, 2023 |
Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 28, 2023 DEF 14A 1 ny20007761x1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| April 3, 2023 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update Three patients now dosed in Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome; encouraging initial reduction in proteinuria has been observed in one patient to date Investigational New Drug (IND) application for ZKN-013 filed for treatment of reces |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| March 31, 2023 |
As filed with the Securities and Exchange Commission on March 31, 2023 S-8 1 tm2310897d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on March 31, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1368850 (State or other jurisdiction of in |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31326 ELOXX PHARMACEUTICALS, IN |
|
| March 31, 2023 |
List of Subsidiaries of the Company. Exhibit 21.1 Subsidiaries of Eloxx Pharmaceuticals, Inc. as of December 31, 2022 Eloxx Pharmaceuticals Ltd., a private limited company organized under the laws of Israel Eloxx Pharmaceuticals (AUS) Pty Ltd., a private limited company organized under the laws of Australia Zikani Therapeutics, Inc., a private corporation organized under the laws of Delaware |
|
| March 31, 2023 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLES FORM S-8 (Form Type) Eloxx Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock |
|
| March 31, 2023 |
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.44 EXECUTION VERSION FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of March 7, 2023 (the “Amendment Signing Date”), is entered into by and among ELOXX PHARMACEUTICALS, INC., a Delaware corporation (“Eloxx”), ZIKANI THERAPEUTICS, INC., a Delaware corporation (“Zikani” and, together with Eloxx, individually |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2023 Eloxx Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31326 84-1368850 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 13, 2023 |
ELOX / Eloxx Pharmaceuticals Inc / ROCHE FINANCE LTD - SC 13G/A Passive Investment SC 13G/A 1 tm236317sc13ga.htm SC 13G/A CUSIP No. 29014R103 SCHEDULE 13G/A Page 1 of 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2 - Exit Filing)* Eloxx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value, $0.01 per share (Title of Class of Securities) 29014R103 (CUSIP Number) December 31, |
|
| December 1, 2022 |
Exhibit 99.1 Eloxx Pharmaceuticals Announces Reverse Stock Split Effective ELOX common stock expected to begin trading on a split-adjusted basis on December 2, 2022 WATERTOWN, MA – December 1, 2022 – Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that its Board of Directors has approved a 1-for-40 |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Comm |
|
| December 1, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ELOXX PHARMACEUTICALS, INC. Eloxx Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: That Article FOURTH of the Amended and Restated Certificate of Incorporation, |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Comm |
|
| November 14, 2022 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update Started proof-of-concept Phase 2 clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations; topline results expected in the first half of 2023 On track to submit IND application for ZKN-013 for the treatment of recessive dystrophic epidermolysi |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUT |
|
| October 31, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as per |
|
| October 17, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as perm |
|
| October 14, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2022 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commi |
|
| September 15, 2022 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no drug-related serious adverse events observed Evidence of activity for E |
|
| September 15, 2022 |
Exhibit 99.2 RARE Thinking for RARE Solutions Topline ELX - 02 Combination Phase 2 Cystic Fibrosis (CF) Results September 14, 2022 / 2 Forward - looking statements This press release contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 199 5. All statements other than statements of present and historical facts contained in this press release, |
|
| September 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Com |
|
| August 15, 2022 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected by the end of the third quarter of 2022 On track to initiate a proof-of-concept clinical trial with ELX-02 in up to eight Alport syndrome patients with nonse |
|
| August 15, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commis |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUTICALS |
|
| July 15, 2022 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| July 15, 2022 |
Letter from Deloitte & Touche LLP, dated July 15, 2022. EX-16.1 2 tm2221060d1ex16-1.htm EXHIBIT 16.1 Exhibit 16.1 Deloitte & Touche LLP 200 Berkeley Street Boston, MA 02116 USA Tel.: +1 617 473 2000 www.deloitte.com July 15, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Eloxx Pharmaceuticals, Inc.'s Form 8-K dated July 15, 2022, and we agree with the statements made in |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| July 5, 2022 |
Exhibit 99.1 Eloxx Pharmaceuticals Announces Changes to Board of Directors Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra step down from the Eloxx board WATERTOWN, MA ? July 5, 2022 ? Eloxx Pharmaceuticals, Inc. (NASD |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| May 10, 2022 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected at the end of the first half of 2022 Expanded d |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissio |
|
| May 6, 2022 |
ELOXX PHARMACEUTICALS, INC. Up to $12,996,794.66 of Common Stock 424B5 1 tm2214756d1424b5.htm 424B5 As Filed Pursuant to Rule 424(b)(5) Registration No. 333-258994 PROSPECTUS SUPPLEMENT (To Prospectus dated August 30, 2021 and the Prospectus Supplement dated September 30, 2021) ELOXX PHARMACEUTICALS, INC. Up to $12,996,794.66 of Common Stock This Prospectus Supplement supplements the prospectus supplement, dated September 30, 2021 (the “ATM Prospectus Supplemen |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUTICAL |
|
| April 29, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ?) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as perm |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| April 4, 2022 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update March 31, 2022 Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-0 |
|
| March 30, 2022 |
List of Subsidiaries of the Company. Exhibit 21.1 Subsidiaries of Eloxx Pharmaceuticals, Inc. as of December 31, 2021 Eloxx Pharmaceuticals Ltd., a private limited company organized under the laws of Israel Eloxx Pharmaceuticals (AUS) Pty Ltd., a private limited company organized under the laws of Australia |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31326 ELOXX PHARMACEUTICALS, IN |
|
| March 30, 2022 |
Description of Registered Securities. Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of our capital stock and certain provisions of our amended and restated certificate of incorporation, as amended, (the ?certificate of incorporation?) and our amended and restated bylaws (the ?bylaws?) are summaries and are qualified in their entirety |
|
| February 14, 2022 |
ELOX / Eloxx Pharmaceuticals Inc / ROCHE FINANCE LTD - SC 13G/A Passive Investment CUSIP No. 29014R103 SCHEDULE 13G/A Page 1 of 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Eloxx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29014R103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this St |
|
| February 3, 2022 |
ELOX / Eloxx Pharmaceuticals Inc / LSP V Cooperatieve U.A. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(a) and Amendments Thereto Filed Pursuant to ? 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* ELOXX PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Secur |
|
| January 5, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commis |
|
| November 17, 2021 |
RARE Thinking for RARE Solutions Topline ELX - 02 Phase 2 Cystic Fibrosis Results November 17, 2021 Exhibit 99.2 RARE Thinking for RARE Solutions Topline ELX - 02 Phase 2 Cystic Fibrosis Results November 17, 2021 / 2 Forward - looking statements This presentation (and the accompanying oral discussion) contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . All statements other than statements of present and historical facts contained in |
|
| November 17, 2021 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Comm |
|
| November 17, 2021 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02 monotherapy results support advancement |
|
| November 9, 2021 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update Data from Monotherapy Arms of Ongoing Phase 2 ELX-02 Cystic Fibrosis (CF) Clinical Trials Expected in Fourth Quarter of 2021 Received FDA Fast Track Designation for ELX-02 for the Treatment of CF Patients with Nonsense Mutations Hosted Call and Webcast on CF Programs Featuring |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commi |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUT |
|
| November 8, 2021 |
Exhibit 10.1 EXECUTION VERSION LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 30, 2021 and is entered into by and among ELOXX PHARMACEUTICALS, Inc., a Delaware corporation (?Eloxx?), ZIKANI THERAPEUTICS, INC., a Delaware corporation (?Zikani? and, together with Eloxx and each other Person party hereto as a borrower from time to time, individually or |
|
| October 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Com |
|
| September 30, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 30, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Comm |
|
| September 30, 2021 |
Exhibit 1.1 ELOXX PHARMACEUTICALS, INC. Shares of Common Stock ($0.01 par value per share) SALES AGREEMENT September 30, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Eloxx Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Leerink LLC (the ?Agent?), as follows: 1. Issuance |
|
| September 30, 2021 |
ELOXX PHARMACEUTICALS, INC. Up to $50,000,000 Common Stock TABLE OF CONTENTS ?As Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-258994? PROSPECTUS SUPPLEMENT (To Prospectus dated August 30, 2021) ELOXX PHARMACEUTICALS, INC. Up to $50,000,000 Common Stock ? We have entered into a Sales Agreement (the ?Sales Agreement?), with SVB Leerink LLC (the ?SVB Leerink?), dated September 30, 2021, relating to the sale of shares of our common stock offered by |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Com |
|
| August 26, 2021 |
Eloxx Pharmaceuticals, Inc. 480 Arsenal Way Watertown, MA 02472 Eloxx Pharmaceuticals, Inc. 480 Arsenal Way Watertown, MA 02472 August 26, 2021 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Re: ELOXX PHARMACEUTICALS, INC. Registration Statement on Form S-3 (Registration No. 333-258994) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act o |
|
| August 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commis |
|
| August 20, 2021 |
As filed with the Securities and Exchange Commission on August 20, 2021 As filed with the Securities and Exchange Commission on August 20, 2021 Registration No. |
|
| August 20, 2021 |
Exhibit 4.3 ELOXX PHARMACEUTICALS, INC. INDENTURE Dated as of August 20, 2021 [] Trustee TABLE OF CONTENTS Page Article I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 Article II. THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 |
|
| August 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commis |
|
| August 17, 2021 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF) Nominated ZKN-013 as Lead Candidate for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and Junctional Epidermolysis Bullosa (JEB) Programs Adva |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUTICALS |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| July 6, 2021 |
Exhibit 99.1 Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021 WATERTOWN, MA ? JULY 6, 2021 ? Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today provided an update on enrollment for the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic |
|
| July 6, 2021 |
Exhibit 10.1 EXECUTION COPY AGREEMENT AND GENERAL RELEASE Eloxx Pharmaceuticals, Inc. (the ?Company?) and Neil Belloff (?Executive?) agree to the following. 1. Transition Period. The period between June 30, 2021, and the Termination Date (as defined below) will be a ?Transition Period,? during which the following will apply: (a) Executive will devote his full-time efforts to his responsibilities a |
|
| June 29, 2021 |
SVON / Sevion Therapeutics, Inc. / Gurnet Point L.P. - SC 13G Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Eloxx Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29014R103 ( |
|
| June 29, 2021 |
Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. |
|
| June 16, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of inco |
|
| June 16, 2021 |
ZIKANI THERAPEUTICS, INC. Index to Unaudited Interim Condensed Financial Statements Exhibit 99.2 ZIKANI THERAPEUTICS, INC. Index to Unaudited Interim Condensed Financial Statements CONDENSED FINANCIAL STATEMENTS CONDENSED BALANCE SHEET 2 CONDENSED STATEMENT OF OPERATIONS 3 CONDENSED STATEMENT OF CASH FLOWS 4 CONDENSED STATEMENT OF CHANGES IN CONVERTIBLE PREFERRRED STOCK AND STOCKHOLDERS? DEFICIT 5 NOTES TO FINANCIAL STATEMENTS 6 ZIKANI THERAPEUTICS, INC. UNAUDITED CONDENSED BALAN |
|
| June 16, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Agreement and Plan of Merger On April 1, 2021, Eloxx Pharmaceuticals, Inc., a Delaware corporation (?Eloxx? or the ?Company?), acquired Zikani Therapeutics, Inc., a Delaware corporation (?Zikani?), pursuant to that certain Agreement and Plan of Merger, dated April 1, 2021 (the ?Merger Agreement?), by and among Eloxx, Delta M |
|
| June 16, 2021 |
Exhibit 99.1 ZIKANI THERAPEUTICS, INC. FINANCIAL STATEMENTS DECEMBER 31, 2020 AND 2019 Independent Auditors? Report To the Board of Directors Zikani Therapeutics, Inc. Watertown, Massachusetts We have audited the accompanying financial statements of Zikani Therapeutics, Inc. (the Company), which comprise the balance sheets as of December 31, 2020 and 2019, and the related statements of operations, |
|
| June 14, 2021 |
CUSIP No. 29014R103 SCHEDULE 13G Page 1 of 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Eloxx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value, $0.01 per share (Title of Class of Securities) 29014R103 (CUSIP Number) April 1, 2021 (Date of Event Which Requires Filing of this Statement) |
|
| May 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissio |
|
| May 27, 2021 |
Exhibit 99.1 Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents May 27, 2021 Leverages TURBO-ZM? Synthetic Chemistry Platform for Designing Oral Macrolide-based Ribosome Modulating Agents (RMAs) Complements ELX-02 program in Phase 2 Clinical Trials for the Treatment of Cystic Fibrosis WALTHAM, Mass., May 27, 2021 (GLOBE NEWSW |
|
| May 21, 2021 |
Exhibit 3 STRATEGIC ALLIANCE AGREEMENT This Strategic Alliance Agreement (the "Agreement ") is made as of August 9, 2018 (the "Effective Date"), by and between Pontifax IV GP LP ("GP4"), Pontifax V GP LP ("GP5") and Pontifax Late Stage GP Ltd ("LS GP"). |
|
| May 21, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2)* ELOXX PHARMACEUTICALS, INC. (Name of Issuer) Common Stock Par Value $0.01 Per Share (Title of Class of Securities) 29014R103 (CUSIP Number) Asaf Shinar Pontifax 14 Shenkar Street Herzliya Pituach 46140, Israel 972-73-7073771 (Name, Address and Telephone Number of Person Authorized to Receive Not |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissio |
|
| May 18, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissio |
|
| May 18, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissio |
|
| May 18, 2021 |
Exhibit 1.1 Execution Copy ELOXX PHARMACEUTICALS, INC. 33,333,334 Shares Common Stock ($0.01 par value) Underwriting Agreement May 13, 2021 B. Riley Securities, Inc. As Representative of the several Underwriters, c/o B. Riley Securities, Inc. 11100 Santa Monica Blvd. Suite 800 Los Angeles, CA 90025 Ladies and Gentlemen: Eloxx Pharmaceuticals, Inc. a corporation organized under the laws of the Stat |
|
| May 18, 2021 |
EXHIBIT 99.1 Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters? Option to Purchase Additional Shares WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) ? Eloxx Pharmaceuticals, Inc. (the ?Company?) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the closing of an underwritten p |
|
| May 17, 2021 |
33,333,334 Shares Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-228430? PROSPECTUS SUPPLEMENT (to Prospectus dated November 26, 2018) 33,333,334 Shares Common Stock We are offering 33,333,334 shares of our common stock. Our common stock is traded on the Nasdaq Global Market under the symbol ?ELOX.? On May 12, 2021, the last reported sale price of our common stock on the Nasdaq Global Ma |
|
| May 13, 2021 |
SUBJECT TO COMPLETION, DATED MAY 13, 2021 TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| May 7, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2021 |
Exhibit 10.5 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this ?First Amendment?) is made as of June 30, 2020, by and between ARE-480 ARSENAL STREET, LLC, a Delaware limited liability company (?Landlord?), and ZIKANI THERAPEUTICS, INC., a Delaware corporation (?Tenant?), formerly known as Macrolide Pharmaceuticals, Inc. RECITALS A. Landlord and Tenant are now parties to that certain Lea |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUTICAL |
|
| May 7, 2021 |
Exhibit 10.4 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made this 28th day of July, 2015, between ARE-480 ARSENAL STREET, LLC, a Delaware limited liability company (?Landlord?), and MACROLIDE PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). Building: 480 Arsenal Street, Watertown, Massachusetts Premises: That portion of the Building containing approximately 12,991 rentable squ |
|
| May 7, 2021 |
Employment offer letter between Eloxx Pharmaceuticals, Inc. and Gary D Rakers dated March 26, 2021 EXHIBIT 10.1 EMPLOYMENT OFFER LETTER March 26, 2021 Gary Rakers [ADDRESS] Dear Gary: On behalf of Eloxx Pharmaceuticals, Inc. (?Eloxx? or the ?Company?), I am pleased to offer you the position of Executive Director, Finance and Accounting, and Treasurer, reporting to the Chief Executive Officer (CEO) or as otherwise designated by the Company, effective March 26, 2021, subject to the approval of th |
|
| May 7, 2021 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Targeted Genetic Therapies Additional Treatment Arm Added to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis (CF) Cystic Fibrosis Foundation (CF Foundation) Increase |
|
| April 29, 2021 |
EXHIBIT 99.1 Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis Fifth Treatment Arm to Evaluate Safety of ELX-02 in Combination with Kalydeco (ivacaftor) Reaffirmed Data Readout for First Four Treatment Arms On Track for Second Half of 2021 WALTHAM, MA ? APRIL 29, 2021 ? Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today announced the addition |
|
| April 29, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| April 20, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| April 20, 2021 |
Exhibit 99.1 RARE Thinking for RARE Solutions Creating a World Leader in Ribosome Targeted Genetic Therapies April 2021 / 2 Forward - looking statements This presentation contains forward - looking statements, which are generally statements that are not historical facts . Forward - looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plan |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Eloxx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 29014R103 (CUSIP Number) Kaasim Mahmood Advent Life Sciences LLP 158-160 North Gower Street London NW1 2ND United Kingdom +44 (0) 207 932 2 |
|
| April 1, 2021 |
Exhibit 99.2 Eloxx Pharmaceuticals Acquires Zikani Therapeutics Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds Preclinical Stage Pipeline in Rare Diseases and Oncology Targeting RNA and Ribosomal Mutations Expect to File IND for First Oral Drug to Treat |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 1, 2021 |
Exhibit 10.3 EXECUTION COPY SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (this ?Agreement?), dated as of the date set forth on the signature page hereto, is entered into by and between Eloxx Pharmaceuticals, Inc. (the ?Company?) and Gregory C. Williams (?Williams?). WHEREAS, Williams has been employed by the Company as the Company?s Chief Executive Officer |
|
| April 1, 2021 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG ELOXX PHARMACEUTICALS, INC. AND Delta Merger Sub Acquisition Corporation AND ZIKANI THERAPEUTICS, INC. DATED AS OF APRIL 1, 2021 Table of Contents Page ARTICLE I DEFINITIONS 2 ARTICLE II THE MERGER 10 Section 2.01 The Merger 10 Section 2.02 Closing 10 Section 2.03 Effective Time 10 Section 2.04 Effects of the Merger 11 Section |
|
| April 1, 2021 |
Exhibit 99.1 Creating a Leader in Ribosomal RNA - Targeted Genetic Therapy Eloxx A cquires Zikani Therapeutics April 1, 2021 This presentation contains forward - looking statements, which are generally statements that are not historical facts . Forward - looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and si |
|
| April 1, 2021 |
Exhibit 10.2 EXECUTION COPY EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the ?Agreement?) between Eloxx Pharmaceuticals, Inc. (the ?Company?), and Vijay Modur (the ?Executive?) is dated as of April 1, 2021 and shall become effective on the date hereof (the ?Effective Date?). W I T N E S S E T H: WHEREAS, the Executive wishes to be employed by the Company and to provide emplo |
|
| April 1, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? ? SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as per |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| April 1, 2021 |
Exhibit 10.1 EXECUTION COPY EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the ?Agreement?) between Eloxx Pharmaceuticals, Inc. (the ?Company?), and Sumit Aggarwal (the ?Executive?) is dated as of April 1, 2021 and shall become effective on the date hereof (the ?Effective Date?). W I T N E S S E T H: WHEREAS, the Executive wishes to be employed by the Company and to provide em |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| March 12, 2021 |
As filed with the Securities and Exchange Commission on March 12, 2021 Registration No. |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31326 ELOXX PHARMACEUTICALS, IN |
|
| March 12, 2021 |
List of Subsidiaries of the Company. EX-21.1 2 elox-ex21110.htm EX-21.1 Exhibit 21.1 Subsidiaries of Eloxx Pharmaceuticals, Inc. as of December 31, 2020 Eloxx Pharmaceuticals Ltd., a private limited company organized under the laws of Israel |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| March 11, 2021 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update We expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of this year We have expanded our global Phase 2 clinical trial beyond the U.S., Europe and Israel; opening additional clinical sites in Australia and Canada Cys |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Eloxx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, USD 0.01 par value per share (Title of Class of Securities) 29014R103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| January 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commi |
|
| January 13, 2021 |
EXHIBIT 99.1 Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support for ELX-02 Global Phase 2 Clinical Trial Program The CF Foundation’s partial funding of the U.S. trial has been extended to partial funding of the global clinical trial program which includes Europe and Israel Expect to report top line data from our Phase 2 cystic fibros |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUT |
|
| November 5, 2020 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Third Quarter 2020 Financial and Operating Results and Provides Business Update Expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of 2021 The independent Safety Review Committees for our Phase 2 cystic fibrosis clinical trial program have allowed dose escalation up to the highest dose level Preclinical studi |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commi |
|
| August 12, 2020 |
EXHIBIT 99.1 Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 Pandemic Waltham, MA. – August 12, 2020 – Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutati |
|
| August 12, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2020 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commis |
|
| August 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUTICALS |
|
| August 6, 2020 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update Enrollment in our Phase 2 clinical trial program for ELX-02 in cystic fibrosis has been resumed in Europe and Israel after being temporarily paused due to the COVID-19 pandemic U.S. FDA has granted orphan drug designation for ELX-02 for the treatment of cystic fibrosis Comple |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| August 4, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| August 4, 2020 |
EXHIBIT 99.1 Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis ELX-02 had previously been granted orphan medicinal product designation for the treatment of Cystic Fibrosis by the European Medicines Agency Waltham, MA. – August 04, 2020 – Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the |
|
| June 17, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2020 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| June 17, 2020 |
EXHIBIT 99.1 Enrollment in Phase 2 Clinical Trial in Cystic Fibrosis Has Been Resumed in Israel and Europe After Being Paused Temporarily in Response to the COVID-19 Pandemic Waltham, MA. – June 17, 2020 – Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other disease |
|
| May 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2020 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissio |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUTICAL |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 tm2018881d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdict |
|
| May 7, 2020 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results and Provides Business Update Completing our Phase 2 clinical trial program for ELX-02 in Cystic Fibrosis remains our highest priority Preclinical studies advancing in autosomal dominant polycystic kidney disease (ADPKD) and inherited retinal disorders Strong balance sheet with $44 million in cash and cash |
|
| April 1, 2020 |
ELOX / Eloxx Pharmaceuticals, Inc. DEF 14A - - DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| April 1, 2020 |
ELOX / Eloxx Pharmaceuticals, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 25, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2020 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| March 25, 2020 |
Exhibit 99.1 Eloxx Pharmaceuticals Provides Update on the Impact of Novel Coronavirus (COVID-19) on Phase 2 Clinical Trials in Cystic Fibrosis Enrollment in our Phase 2 Cystic Fibrosis Trials has been paused temporarily in response to the COVID-19 pandemic Cystic Fibrosis patients, especially those with nonsense mutations, are at increased risk of severe illness Waltham, MA. – March 25, 2020 – Elo |
|
| March 13, 2020 |
8-K/A 1 tm2012703d18ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2020 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-13 |
|
| March 13, 2020 |
SVOND / Eloxx Pharmaceuticals, Inc. / Lsp V Cooperatieve U.a. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* ELOXX PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class |
|
| March 6, 2020 |
EXHIBIT 10.42 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) between Eloxx Pharmaceuticals, Inc. (the “Company”), and Gregory C. Williams (the “Executive”) is dated as of February 25, 2020 and shall become effective on the date hereof (the “Effective Date”). W I T N E S S E T H: WHEREAS, the Company and the Executive have entered into an Executive Employment A |
|
| March 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31326 ELOXX PHARMACEUTICALS, IN |
|
| March 6, 2020 |
List of Subsidiaries of the Company. Exhibit 21.1 Subsidiaries of Eloxx Pharmaceuticals, Inc. as of December 31, 2019 Eloxx Pharmaceuticals Ltd., a private limited company organized under the laws of Israel |
|
| March 6, 2020 |
John van Duzer Stock Option Grant Notice and Stock Option Agreement, dated February 22, 2018. Exhibit 99.7 Eloxx Pharmaceuticals, Inc. Stock Option Grant Notice (Inducement Grant Outside of the Amended and Restated Sevion Therapeutics, Inc. 2008 Incentive Compensation Plan) As an inducement material to Participant’s entering into employment with Eloxx Pharmaceuticals, Inc.1 (the “Corporation”), the Corporation hereby grants to Optionee an option to purchase the number of shares of the Corp |
|
| March 6, 2020 |
EXHIBIT 10.43 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) between Eloxx Pharmaceuticals, Inc. (the “Company”), and Neil Belloff (the “Executive”) is dated as of February 25, 2020 and shall become effective on the date hereof (the “Effective Date”). W I T N E S S E T H: WHEREAS, the Company and the Executive have entered into an Executive Employment Agreemen |
|
| March 6, 2020 |
EXHIBIT 10.44 Employment offer letter September 19, 2019 Stephen MacDonald [ADDRESS] Dear Stephen: On behalf of Eloxx Pharmaceuticals, I am pleased to offer you the position of Executive Director, Accounting and Corporate Controller reporting to Greg Weaver, Chief Financial Officer. Your start date will be October 21, 2019. The terms of the offer are as follows: Base Salary: Your starting salary w |
|
| March 6, 2020 |
ELOX / Eloxx Pharmaceuticals, Inc. S-8 - - FORM S-8 As filed with the Securities and Exchange Commission on March 6, 2020 Registration No. |
|
| March 5, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2020 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| March 5, 2020 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial and Operating Results and Provides Business Update Topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 in H1 2020 Realignment strengthens commitment to Cystic Fibrosis and strategic flexibility by extending cash runway through the end of 2021 Strong balance sheet with $56.3 million in cash and c |
|
| February 26, 2020 |
Exhibit 99.1 Eloxx Strengthens its Commitment to Cystic Fibrosis Through Reallocating Resources Reiterate topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 expected in H1 2020 Results from clinical and preclinical research to date support Company’s prioritization of Cystic Fibrosis programs Headcount realignment to reduce operating expenses and significantly extend funding of op |
|
| February 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2020 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Comm |
|
| February 12, 2020 |
SVOND / Eloxx Pharmaceuticals, Inc. / MENORA MIVTACHIM HOLDINGS LTD. - SC 13G/A Passive Investment SC 13G/A 1 zk2023977.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Eloxx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, USD 0.01 par value per share (Title of Class of Securities) 29014R103 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Ch |
|
| January 14, 2020 |
EXHIBIT 99.1 Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech ShowcaseÔ Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 2020 Positive Phase 2 topline data reported for ELX-02 in nephropathic cystinosis from the first t |
|
| January 14, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2020 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commi |
|
| November 6, 2019 |
Change in Control Severance Benefit Plan Exhibit 10.1 Eloxx Pharmaceuticals, Inc. Change in Control Severance Benefit Plan Approved by the Board of Directors: September 17, 2019 Section 1.Introduction. The Eloxx Pharmaceuticals, Inc. Change in Control Severance Benefit Plan (the “Plan”) is hereby established effective September 17, 2019 (the “Effective Date”). The purpose of the Plan is to provide for the payment of severance benefits to |
|
| November 6, 2019 |
ELOX / Eloxx Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUT |
|
| November 5, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2019 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commi |
|
| November 5, 2019 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results and Provides Business Update -Presented Positive Phase 1 Data from SAD and MAD Studies at North American Cystic Fibrosis Conference -On track to report top line Phase 2 data in nephropathic cystinosis this quarter, preliminary results show cystine reduction with 1mg/kg dose -Actively enrolling Phase 2 cys |
|
| August 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2019 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| August 7, 2019 |
EXHIBIT 99.1 Eloxx Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results and Provides Business Update Phase 2 cystic fibrosis clinical trial IND is open in the U.S., protocol endorsed by the Cystic Fibrosis Foundation (CFF) Initiated a Phase 2 clinical trial for ELX-02 in cystinosis in Canada and received non-dilutive funding from Genome Quebec and Genome Canada On track to r |
|
| August 7, 2019 |
ELOX / Eloxx Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUTICALS |
|
| August 5, 2019 |
Exhibit 99.1 Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial for ELX-02 in Cystinosis Dr. Paul Goodyer, Professor of Pediatrics at McGill University and recognized leader in hereditary renal disease, is the principal investigator in the Phase 2 clinical trial On track to report top line data from Phase 2 clinical trials for ELX-02 in cystic fibrosis and cystinosis in the U.S., |
|
| August 5, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2019 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commiss |
|
| July 31, 2019 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2019 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| July 31, 2019 |
Exhibit 99.1 Eloxx Pharmaceuticals Announces Open Investigational New Drug Application (IND) for a Phase 2 Clinical Trial of ELX-02 in Cystic Fibrosis Patients with the G542X Mutation in the US and Protocol Endorsement from the Cystic Fibrosis Foundation (CFF) On track to report top line data from Phase 2 clinical trials for ELX-02 in cystic fibrosis and cystinosis in the U.S., Europe, Israel, and |
|
| June 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ELOXX PHARMACEUTICALS, INC. (Name of Issuer) Common Stock Par Value $0.01 Per Share (Title of Class of Securities) 29014R103 (CUSIP Number) Asaf Shinar Pontifax 14 Shenkar Street Herzliya Pituach 46140, Israel 972-9-9725617 (Name, Address and Telephone N |
|
| June 26, 2019 |
POWER OF ATTORNEY (For Executing Form ID, Forms 3, 4 and 5 and Schedule 13D and 13G) Exhibit 1.1 POWER OF ATTORNEY (For Executing Form ID, Forms 3, 4 and 5 and Schedule 13D and 13G) Know all by these presents that the undersigned hereby constitutes and appoints each of Miguel Vega and Jonathan Browalski of Cooley LLP and Robert Ward, Gregory Weaver and Neil Belloff of Eloxx Pharmaceuticals, Inc. (the “Company”), the undersigned’s true and lawful attorneys-in-fact and agents to: (1 |
|
| June 24, 2019 |
Exhibit 99.1 Eloxx Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Waltham, MA. – June 24, 2019– Eloxx Pharmaceuticals, Inc. (“Eloxx”) (Nasdaq: ELOX) today announced the closing of its underwritten public offering of 3,833,334 shares of its common stock, which includes the full exercise of the underwriters |
|
| June 24, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2019 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissi |
|
| June 21, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2019 (June 19, 2019) Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorp |
|
| June 21, 2019 |
Exhibit 1.1 EXECUTION VERSION ELOXX PHARMACEUTICALS, INC. 3,333,334 Shares Common Stock ($0.01 par value) Underwriting Agreement New York, New York June 20, 2019 Citigroup Global Markets Inc. Piper Jaffray & Co. As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Piper Jaffray & Co. 800 Nicolette Mall Minneapolis, Minn |
|
| June 20, 2019 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-228430 PROSPECTUS SUPPLEMENT (to Prospectus dated November 26, 2018) 3,333,334 Shares Common Stock We are offering 3,333,334 shares of our common stock. Our common stock is traded on the Nasdaq Global Market under the symbol “ELOX.” On June 19, 2019, the last reported sale price of our common stock on the Nasdaq Global Marke |
|
| June 20, 2019 |
Eloxx Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Stock Exhibit 99.2 Eloxx Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Stock Waltham, MA. – June 20, 2019– Eloxx Pharmaceuticals, Inc. (“Eloxx”) (Nasdaq: ELOX) today announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock at a price to the public of $9.00 per share. The gross proceeds to Eloxx from the offering are expected to be ap |
|
| June 20, 2019 |
Eloxx Pharmaceuticals Announces Proposed Public Offering of Common Stock Exhibit 99.1 Eloxx Pharmaceuticals Announces Proposed Public Offering of Common Stock Waltham, MA. – June 19, 2019– Eloxx Pharmaceuticals, Inc. (“Eloxx”) (Nasdaq: ELOX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, subject to market and other conditions. Eloxx expects to grant the underwriters an option to purchase up to an additio |
|
| June 20, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2019 (June 19, 2019) Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorpor |
|
| June 20, 2019 |
Exhibit 1.1 EXECUTION VERSION ELOXX PHARMACEUTICALS, INC. 3,333,334 Shares Common Stock ($0.01 par value) Underwriting Agreement New York, New York June 20, 2019 Citigroup Global Markets Inc. Piper Jaffray & Co. As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Piper Jaffray & Co. 800 Nicolette Mall Minneapolis, Minn |
|
| June 19, 2019 |
SUBJECT TO COMPLETION, DATED JUNE 19, 2019 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-228430 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not offers to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction wher |
|
| May 30, 2019 |
POWER OF ATTORNEY (For Executing Form ID, Forms 3, 4 and 5 and Schedule 13D and 13G) POWER OF ATTORNEY (For Executing Form ID, Forms 3, 4 and 5 and Schedule 13D and 13G) Know all by these presents that the undersigned hereby constitutes and appoints each of Miguel Vega and Jonathan Browalski of Cooley LLP and Robert Ward, Gregory Weaver and Neil Belloff of Eloxx Pharmaceuticals, Inc. |
|
| May 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2019 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commissio |
|
| May 9, 2019 |
Exhibit 99.1 Eloxx Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results and Provides Business Update Positive new preclinical data for Eloxx ERSG molecules presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting May 2, 2019 demonstrated: à dose dependent restoration of missing protein of Usher Syndrome nonsense mutations, à encouraging |
|
| May 9, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2019 Eloxx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31326 84-1368850 (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2019 |
ELOX / Eloxx Pharmaceuticals, Inc. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31326 ELOXX PHARMACEUTICAL |
|
| May 9, 2019 |
EX-99.2 Exhibit 2 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Steven D. Rubin, with full power to act singly, his true and lawful attorney-in-fact to: (i) sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a general partner of any partnership or lim |
|
| May 9, 2019 |
SVOND / Eloxx Pharmaceuticals, Inc. / Opko Health, Inc. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 ELOXX PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 29014R103 (CUSIP |
|
| May 9, 2019 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) with respect to Eloxx Pharmaceuticals, |
|
| April 29, 2019 |
EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G/A (including any and all amendments thereto) with respect to the Common Stock, par value $0. |
|
| April 29, 2019 |
SVOND / Eloxx Pharmaceuticals, Inc. / Catalyst Cel Management Ltd. - SC 13G/A Passive Investment CUSIP No. 29014R103 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (RULE 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) ELOXX PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 29014R103 (CUSIP Number) April 29, 2019 (Date of Event Which Requires Filing of thi |
|
| April 5, 2019 |
ELOX / Eloxx Pharmaceuticals, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 5, 2019 |
ELOX / Eloxx Pharmaceuticals, Inc. DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
